Mavacamten

Type: API

Usage: Hypertrophic cardiomyopathy

Technical description
Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.

IUPAC name: 6-[[(1S)-1-phenylethyl]amino]-3-propan-2-yl-1H-pyrimidine-2,4-dione.

Molecular formula: C₁₅H₁₉N₃O₂

Molecular Weight: 273.33 g/mol

Class: Mavacamten is the first selective, allosteric, and reversible inhibitor of cardiac myosin.

Synonyms: MYK-461, SAR-439152.